ClinicalTrials.gg
TerminatedNCT00929162Updated Aug 7, 2012Results posted

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

A Phase 2 interventional study of ZD4054 Zibotentan and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy, sponsored by AstraZeneca. Terminated at 20 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-07.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Why this study was terminated
Primary objective of the trial was not met and so there was no benefit in collecting further information

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.

02

Conditions studied

  • Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

Keywords

  • ovarian
  • cancer
  • chemotherapy
  • sensitive
  • ZD4054
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 120 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven diagnosis of: - Epithelial ovarian carcinoma - Fallopian tube carcinoma - Primary serous peritoneal carcinoma
  • Radiologically documented according to criteria assessed by Computerised Tomography (CT) or Magnetic Resonance Imaging MRI) or radiologically documented non-measurable (but evaluable) disease.
  • Advanced disease not amenable to curative surgery or radiotherapy at the time of study entry with evidence of disease recurrence or progression at least 6 months following treatment cessation of platinum- containing therapy

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of central nervous system (CNS)
  • Non-epithelial ovarian cancer, including malignant mixed Mullerian tumours and mucinous carcinoma of the peritoneum
  • Tumour of borderline
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    ZD4054 + paclitaxel + carboplatin

    ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks

    Drug: ZD4054 Zibotentan · Drug: Paclitaxel · Drug: Carboplatin

  • Placebo comparator
    Placebo + paclitaxel + carboplatin

    Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks

    Drug: Paclitaxel · Drug: Carboplatin · Drug: Placebo

Interventions

  • 10 mg oral tablets once daily

  • 175mg/m2 IV on day 1 every 3 weeks

  • Carboplatin AUC of 5.0 IV on day 1 every 3 weeks

  • DrugPlacebo

    matching placebo for ZD4054 10 mg

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method.

    Time frame: Patients were followed for progression up to 2 years

Secondary outcomes

  1. Overall Survival

    Median time (in months) from randomisation until death using the Kaplan-Meier method.

    Time frame: Patients were followed for survival up to 2 years

  2. Tumour Response Rate

    Objective response rate defined as participants with a complete or partial response according to RECIST

    Time frame: While receiving paclitaxel + carboplatin study visits were aliged with its administration ie every 3 weeks, then every 6 weeks (up to 2 years)

07

Results

Posted Jun 6, 2012

Participant flow

132 patients with advanced ovarian cancer sensitive to platinum-based chemotherapy were recruited between 26th June 2009 and 1st June 2011.

Participant flow — Overall Study
MilestoneZD4054+Paclitaxel+CarboplatinPlacebo+Paclitaxel+Carboplatin
Started5961
Patients who received treatment5858
Completed1119
Not completed4842
Withdrew: Adverse event85
Withdrew: Withdrawal by subject31
Withdrew: Protocol violation3230
Withdrew: Other termination reason56

Outcome measures

PrimaryProgression Free Survival

Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method.

Time frame:
Patients were followed for progression up to 2 years
Reported as:
Median · Months
Progression Free Survival
MonthsZD4054+Paclitaxel+CarboplatinPlacebo+Paclitaxel+Carboplatin
Progression Free Survival7.6 (6.6 to 10.2)10.0 (7.1 to 12.2)
SecondaryOverall Survival

Median time (in months) from randomisation until death using the Kaplan-Meier method.

Time frame:
Patients were followed for survival up to 2 years

No measurements were reported for this outcome.

SecondaryTumour Response Rate

Objective response rate defined as participants with a complete or partial response according to RECIST

Time frame:
While receiving paclitaxel + carboplatin study visits were aliged with its administration ie every 3 weeks, then every 6 weeks (up to 2 years)
Reported as:
Number · Participants
Tumour Response Rate
ParticipantsZD4054+Paclitaxel+CarboplatinPlacebo+Paclitaxel+Carboplatin
Tumour Response Rate2134

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZD4054+Paclitaxel+Carboplatin—19/58 (32.8%)57/58 (98.3%)
Placebo+Paclitaxel+Carboplatin—13/58 (22.4%)58/58 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventZD4054+Paclitaxel+CarboplatinPlacebo+Paclitaxel+Carboplatin
Drug HypersensitivityImmune system disorders5/584/58
Abdominal PainGastrointestinal disorders4/581/58
SubileusGastrointestinal disorders4/580/58
IleusGastrointestinal disorders3/580/58
ConstipationGastrointestinal disorders2/581/58
PyrexiaGeneral disorders0/582/58
AnaemiaBlood and lymphatic system disorders1/580/58
Coronary Artery OcclusionCardiac disorders0/581/58
Ischaemic CardiomyopathyCardiac disorders0/581/58
AscitesGastrointestinal disorders1/581/58
Most frequent other events
Showing 10 of 51
Most frequent other events
EventZD4054+Paclitaxel+CarboplatinPlacebo+Paclitaxel+Carboplatin
NauseaGastrointestinal disorders28/5831/58
AnaemiaBlood and lymphatic system disorders30/5825/58
AlopeciaSkin and subcutaneous tissue disorders28/5828/58
FatigueGeneral disorders20/5827/58
HeadacheNervous system disorders27/5817/58
NeutropeniaBlood and lymphatic system disorders26/5822/58
ConstipationGastrointestinal disorders24/5819/58
VomitingGastrointestinal disorders21/5820/58
LeukopeniaBlood and lymphatic system disorders20/5815/58
Abdominal PainGastrointestinal disorders16/5820/58

Baseline characteristics

Age Continuous
Age Continuous(Years)ZD4054+Paclitaxel+CarboplatinPlacebo+Paclitaxel+CarboplatinTotal
Overall57.4 ± 11.9856.6 ± 11.0757.0 ± 11.49
Sex: Female, Male
Sex: Female, Male(Participants)ZD4054+Paclitaxel+CarboplatinPlacebo+Paclitaxel+CarboplatinTotal
Female5961120
Male000
08

Study locations

20 sites
  • Research Site
    Berlin, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Dusseldorf, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Karlsruhe, Germany
  • Research Site
    Kassel, Germany
  • Research Site
    Kiel, Germany
  • Research Site
    Lich, Germany
  • Research Site
    Magdeburg, Germany
  • Research Site
    Marburg, Germany
  • Research Site
    Munchen, Germany
  • Research Site
    Rostock, Germany
  • Research Site
    Wiesbaden, Germany
  • Research Site
    Milano, MI, Italy
  • Research Site
    Perugia, PG, Italy
  • Research Site
    Aviano, PN, Italy
  • Research Site
    Campobasso, Italy
  • Research Site
    Modena, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Roma, Italy
09

References and documents

Publications

  • Cognetti F, Bagnato A, Colombo N, Savarese A, Scambia G, Sehouli J, Wimberger P, Sorio R, Harter P, Mari E, McIntosh S, Nathan F, Pemberton K, Baumann K. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). Gynecol Oncol. 2013 Jul;130(1):31-7. doi: 10.1016/j.ygyno.2012.12.004. Epub 2012 Dec 9. PubMed 23234805 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2009
First posted
Jun 26, 2009
Start
Jun 2009
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Jun 6, 2012
Last update
Aug 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00929162
Lead sponsor
AstraZeneca
Collaborators
ISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALI
Responsible party
Sponsor
First posted
Jun 26, 2009
Start date
Jun 2009
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Jun 6, 2012
Last update
Aug 7, 2012

Study contacts

Tom Morris
study director · AstraZeneca, Alderley Park
Ian Thomas
study chair · AstraZeneca, Alderley Park

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion